Placental deficiency during maternal SARS-CoV-2 infection.
Adult
Antibodies, Viral
/ blood
COVID-19
/ complications
Cohort Studies
Female
Fetal Blood
/ immunology
Humans
Immunity, Maternally-Acquired
/ immunology
Infant, Newborn
Infectious Disease Transmission, Vertical
Placenta
/ chemistry
Placenta Diseases
/ pathology
Pregnancy
Pregnancy Complications, Infectious
/ pathology
Pregnancy Outcome
Premature Birth
Prospective Studies
SARS-CoV-2
/ isolation & purification
Severity of Illness Index
Spike Glycoprotein, Coronavirus
/ analysis
COVID-19
Placental pathological findings
Pregnancy
SARS-CoV-2 infection
Journal
Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
22
05
2021
revised:
22
09
2021
accepted:
21
10
2021
pubmed:
13
11
2021
medline:
22
1
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
Maternal anti-SARS-CoV-2 Spike antibodies can cross the placenta during pregnancy, and neonates born to infected mothers have acquired antibodies at birth. Few studies reported data on the histopathological changes of the placenta during infection and placental infection. SARS-CoV-2 infection may cause impaired development of the placenta, thus predisposing maternal and fetal unfavorable outcomes. The prospective study aims to evaluate the risk of vertical transmission of SARS-CoV-2 and placental passage of anti-Spike antibodies as well as the impact of clinical severity on placental structures. This is a prospective cohort study on 30 pregnant women infected by SARS-CoV-2 with their neonates. The demographic features and pregnancy outcomes were collected. Gross and microscopic examinations of the placentas were done. Maternal and umbilical cord sera were obtained at the time of delivery. Nasopharyngeal swabs were collected from neonates immediately after birth. The concentrations of total anti-SARS-CoV-2 Spike antibodies were higher in pregnant women with moderate to severe/critical disease. The maternal total anti-SARS-CoV-2 Spike levels were correlated with those of neonatal levels. The rate of placental abnormalities is high in the mothers with severe disease, and those with positive anti-SARS-CoV-2 IgM. All neonates had negative nasopharyngeal swabs for SARS- CoV-2 infections and all placentas were negative in immunohistochemical staining for Spike protein. The maternally derived anti-SARS-CoV-2 Spike antibody can transmit to neonates born to infected mothers regardless of gestational age. Our results indicated that the disease severity is associated with ischemic placental pathology which may result in adverse pregnancy outcomes.
Identifiants
pubmed: 34768168
pii: S0143-4004(21)00630-5
doi: 10.1016/j.placenta.2021.10.012
pmc: PMC8539206
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-56Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Am J Obstet Gynecol. 2007 Sep;197(3):281.e1-8
pubmed: 17826421
Front Immunol. 2019 Oct 18;10:2317
pubmed: 31681264
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
Cureus. 2021 Feb 6;13(2):e13184
pubmed: 33717728
Nat Commun. 2020 Jul 14;11(1):3572
pubmed: 32665677
Am J Obstet Gynecol. 2006 Sep;195(3):633-42
pubmed: 16846587
JAMA Pediatr. 2020 Jul 1;174(7):722-725
pubmed: 32215598
Arch Pathol Lab Med. 2016 Jul;140(7):698-713
pubmed: 27223167
Physiol Rev. 2021 Jan 1;101(1):303-318
pubmed: 32969772
Clin Dev Immunol. 2012;2012:985646
pubmed: 22235228
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Med Virol. 2021 Mar;93(3):1810-1813
pubmed: 33073377
JAMA Netw Open. 2020 Dec 1;3(12):e2030455
pubmed: 33351086
Acta Obstet Gynecol Scand. 2020 May;99(5):565-568
pubmed: 32277845
Lancet Infect Dis. 2020 May;20(5):559-564
pubmed: 32220284
J Reprod Immunol. 2017 Sep;123:65-71
pubmed: 28941880
APMIS. 2018 Jul;126(7):570-588
pubmed: 30129129
Front Immunol. 2021 May 26;12:685919
pubmed: 34122449
Lancet Glob Health. 2021 Jun;9(6):e759-e772
pubmed: 33811827
Am J Obstet Gynecol MFM. 2020 May;2(2):100118
pubmed: 32292903
Cell Host Microbe. 2017 May 10;21(5):561-567
pubmed: 28494237
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100211
pubmed: 32838277
Histopathology. 2020 Dec;77(6):994-999
pubmed: 32692408
Obstet Gynecol. 2019 Jan;133(1):1
pubmed: 30575675
Clin Microbiol Infect. 2021 Jan;27(1):36-46
pubmed: 33148440
BMJ Open. 2021 Jul 7;11(7):e053036
pubmed: 34234001
World J Hepatol. 2014 Aug 27;6(8):538-48
pubmed: 25232447
J Clin Invest. 2020 Sep 1;130(9):4947-4953
pubmed: 32573498
Am J Pathol. 2006 Apr;168(4):1210-26
pubmed: 16565496
Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:490-501
pubmed: 32795828
Infect Dis Obstet Gynecol. 2014;2014:768380
pubmed: 24693211
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
JAMA. 2020 May 12;323(18):1846-1848
pubmed: 32215581
Clin Infect Dis. 2020 Jul 28;71(15):844-846
pubmed: 32119083
BJOG. 2020 Oct;127(11):1324-1336
pubmed: 32531146
Am J Perinatol. 2020 Jun;37(8):861-865
pubmed: 32305046
JAMA. 2020 May 12;323(18):1848-1849
pubmed: 32215589
Am J Obstet Gynecol MFM. 2020 Aug;2(3):100145
pubmed: 32427221
Eur J Med Res. 2020 Sep 4;25(1):39
pubmed: 32887660
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
BJOG. 2020 Nov;127(12):1548-1556
pubmed: 32633022
Am J Obstet Gynecol MFM. 2020 May;2(2):100107
pubmed: 32292902
Am J Obstet Gynecol. 2021 Jan;224(1):35-53.e3
pubmed: 32739398
JAMA Pediatr. 2021 Jun 1;175(6):594-600
pubmed: 33512440
Placenta. 2013 Aug;34(8):657-62
pubmed: 23684378
Transl Pediatr. 2020 Feb;9(1):51-60
pubmed: 32154135
JAMA Pediatr. 2021 Feb 1;175(2):157-167
pubmed: 33044493
Nat Commun. 2020 Oct 12;11(1):5128
pubmed: 33046695
Front Immunol. 2020 Mar 31;11:555
pubmed: 32296443
JAMA Pediatr. 2021 Aug 1;175(8):817-826
pubmed: 33885740
J Clin Invest. 2017 May 1;127(5):1591-1599
pubmed: 28459427